Takeda Pharmaceutical: nieuwe medicijntoepassing in Japan voor Copaxone® subcutane injectie 20 mg spuit, een geneesmiddel voor de behandeling van multiple sclerose
OSAKA, Japan—(BUSINESS WIRE)– Takeda Pharmaceutical Company Limited ( TOKYO:4502)heeft vandaag goedkeuring verkregen voor de nieuwe medicijntoepassing voor Copaxone® subcutane injectie 20 mg spuit (generieke naam: glatirameeracetaat), een geneesmiddel voor de behandeling van multiple sclerose, van het Japanse ministerie van gezondheid, arbeid en welzijn.
Het door Pharmaceutical Industries Ltd. ( Teva ) ontwikkelde Copaxone® is een subcutane injectie die een keer per dag moet worden toegediend om een terugval van multiple sclerose te voorkomen. Copaxone® is een van de meest gebruikte geneesmiddelen in multiple sclerosetherapieën en is in meer dan vijftig landen goedgekeurd.
Takeda Pharmaceutical: New Drug Application Approval in Japan for Copaxone® Subcutaneous Injection 20 mg Syringe, a Drug for the Treatment of Multiple Sclerosis
OSAKA, Japan–(BUSINESS WIRE)– Takeda Pharmaceutical Company Limited ( TOKYO:4502) today obtained the New Drug Application approval for Copaxone ® Subcutaneous Injection 20 mg Syringe (generic name: glatiramer acetate), a drug for the treatment of multiple sclerosis, from the Japanese Ministry of Health, Labour and Welfare.
Developed by Teva Pharmaceutical Industries Ltd. (Teva), Copaxone ® is a subcutaneous injection administered once daily to prevent the relapse of multiple sclerosis. Copaxone ® is one of the most frequently-used drugs in multiple sclerosis therapy and is approved in more than 50 countries worldwide.
In Japan, glatiramer acetate was developed as an Unapproved New Drug by Teva Pharmaceutical K.K., a wholly owned subsidiary of Teva, at the request of the Japanese Ministry of Health, Labour and Welfare. In March, 2013, Takeda and Teva signed a licensing agreement in which Teva granted Takeda the right to commercialize glatiramer acetate in Japan. Takeda submitted the NDA in December 2014 under the terms of this agreement.
The approval is based on the safety and efficacy results of an open-label, 52-week clinical trial conducted in Japan by Teva Pharmaceutical K.K. in patients with relapsing-remitting multiple sclerosis as well as 3 clinical trials from overseas conducted by Teva in patients with relapsing-remitting multiple sclerosis.
Granting of this approval in Japan represents an extremely important milestone for Takeda, and we expect that this drug, which is the first-line therapy overseas for relapsing-remitting multiple sclerosis, can contribute to the therapy of Japanese patients with multiple sclerosis. We will continue to make efforts to deliver drugs that are needed by patients and healthcare professionals.
|
Overview of Copaxone |
||
| Brand name | Copaxone ® Subcutaneous Injection 20 mg Syringe | |
| Generic name | Glatiramer acetate | |
| Indications | Prevention of relapse of multiple sclerosis | |
| Dosage and administration | The usual adult dosage for subcutaneous injection is 20 mg of glatiramer acetate once a day. | |
About Glatiramer Acetate
Glatiramer acetate is indicated for the prevention of relapse frequency of recurrent multiple sclerosis outside Japan. The most common side effects of the medicine are injection site reactions (erythema, pain, mass, pruritus, and edema). It is now approved in more than 50 countries worldwide, including the United States, Russia, Canada, Mexico, Australia, Israel, and all European countries.
About Multiple Sclerosis
Multiple sclerosis is believed to be an autoimmune disease, the cardinal sign of which is inflammatory demyelination of the central nervous system characterized by demyelinating plaques in the brain and the spinal cord. Common symptoms include visual problems, ocular motor abnormality, paresthesia, muscle weakness, spasticity, urinary dysfunction, and cognitive impairment. The disease is categorized into three types: (1) a primary progressive type which takes a chronic progressive course from the onset, (2) a relapsing-remitting type which repeats a relapse and remission, and (3) a secondary progressive type which shifts to the progressive course later. More than 80% of patients are categorized into the relapsing-remitting type. The morbidity in patients is estimated to be approximately 18,000 in Japan, and its prevalence shows an increasing trend.
About Takeda Pharmaceutical Company Limited
Located in Osaka, Japan, Takeda ( TOKYO:4502) is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for people worldwide through leading innovation in medicine.
Additional information about Takeda is available through its corporate website, www.takeda.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150928005506/en/
Contacts
Media Contact
Takeda Pharmaceutical Company Limited
Ryoko Omichi, +81 3 3278 2665
JPBU Communications
ryoko.omichi@takeda.com
or
Kaz umi Kobayashi, +81 3 3278 2095
CCPA Corporate Communications
kazumi.kobayashi@takeda.com